Learn more in our training program.
Join our membership network.
Attend our events and collaborate.
Add your voice to our policy matters.
Get involved in our genetic registry.
Donate to our cause.
The Latino Cancer Institute (TLCI) is a nationwide community and research network dedicated to solving the issues and burden of Latino cancer.
Cancer is the leading cause of death among Hispanics/Latinos in the US. Through more public education, community resources and access to care, survival rates are improving.
Breast cancer is the leading cause of cancer death among Hispanic/Latino women. Local community outreach programs have a direct impact on woman being diagnosed and receiving treatment earlier.
Lung cancer is the leading cause of cancer death among Hispanic/Latino men. With strong public messaging, smoking rates are starting to drop in Latino communities.
Taking up the fight to change the Latino cancer landscape are the many dedicated agencies serving their communities throughout the country. Locate the one nearest you HERE.
For over 20 years, Founder Ysabel Duron has played a vital role in bringing together those dedicated to making a difference in the Latino cancer landscape. From cancer community workers and caregivers to international medical researchers and policymakers, Ysabel has forged important alliances in a field crowded with many competing interests and agendas.
It takes a savvy insider who has traveled this terrain far and wide to help the Latino cancer community at-large continue changing the landscape. TLCI offers the definitive road map.
There are currently no upcoming events.
The Latino Cancer Institute acts as a network for agencies, linking members to share knowledge and best practices. Connecting colleagues, peers and institutions is critical to The Institute’s ongoing mission to amplify and disseminate outstanding work in the cancer arena, and to support one another.
The Latino Cancer Institute provides opportunities to network, learn and collaborate with stakeholders in the cancer landscape including Latino cancer researchers.
The Latino Cancer Institute leverages our united voice at the national table to advance Latino cancer concerns including education, services, funding, and research. Our aim is to be heard, understood and included in any proposed policy.
As a nonprofit organization, we rely on philanthropy and grants in our mission to support other agencies. Your funding allows us to continue the development of new programs and tools we can share with those making a difference in the lives of Latino cancer patients, survivors, and their caregivers.
A study provides insights into the diversity of cancer-associated fibroblasts in white and black skin cancer and describes their different immunomodulatory roles in the tumor environment. The results are relevant for the development of novel skin cancer therapies, particularly in the field of immunotherapy.
Cell-to-cell communication through nanosized particles, working as messengers and carriers, can now be analyzed in a whole new way, thanks to a new method involving CRISPR gene-editing technology. The particles, known as small extracellular vesicles (sEVs), play an important role in the spread of disease and as potential drug carriers. The newly developed system, named CIBER, enables thousands of genes to be studied at once, by labeling sEVs with a kind of RNA 'barcode.' With this, researchers hope to find what factors are involved in sEV release from host cells. This will help advance our understanding of basic sEV biology and may aid in the development of new treatments for diseases, such as cancer.
New research now can identify more proteins, or biomarkers, in blood plasma, including those linked to specific diseases like cancer. By identifying these biomarkers earlier, medical researchers can create better diagnostic tests and drugs that target diseases sooner, improving patient outcomes.
A randomized, phase 2 clinical trial shows that adding high-dose, intravenous (IV) vitamin C to chemotherapy doubles the overall survival of patients with late-stage metastatic pancreatic cancer from eight months to 16 months. The finding adds to mounting evidence of the benefits of high-dose, IV vitamin C in treating cancer.
A novel test enables real-time monitoring of T cells that have been engineered to fight cancer, after re-introduction into the body of a cancer patient. This simple and innovative test provides clinicians with the ability to track the function of these cancer-fighting cells over the course of the treatment.
Researchers have discovered a significant association between specific Epstein-Barr virus (EBV) variants and nasopharyngeal carcinoma (NPC). NPC is a cancer notably prevalent in southern China, where it is 20 times more common than in non-endemic regions of the world.
